These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31991869)

  • 1. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
    Chuma M; Uojima H; Numata K; Hidaka H; Toyoda H; Hiraoka A; Tada T; Hirose S; Atsukawa M; Itokawa N; Arai T; Kako M; Nakazawa T; Wada N; Iwasaki S; Miura Y; Hishiki S; Nishigori S; Morimoto M; Hattori N; Ogushi K; Nozaki A; Fukuda H; Kagawa T; Michitaka K; Kumada T; Maeda S
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
    Shigesawa T; Suda G; Kimura M; Shimazaki T; Maehara O; Yamada R; Kitagataya T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    JGH Open; 2020 Oct; 4(5):880-888. PubMed ID: 33102759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma.
    Hsu PY; Liang PC; Chang WT; Lu MY; Wang WH; Chuang SC; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Chuang WL; Huang CF; Huang JF; Yu ML
    Am J Cancer Res; 2022; 12(12):5576-5588. PubMed ID: 36628276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    Shigesawa T; Suda G; Kimura M; Maehara O; Tokuchi Y; Kubo A; Yamada R; Furuya K; Baba M; Kitagataya T; Suzuki K; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    PLoS One; 2021; 16(3):e0247728. PubMed ID: 33647018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.
    Ono A; Aikata H; Yamauchi M; Kodama K; Ohishi W; Kishi T; Ohya K; Teraoka Y; Osawa M; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Abe-Chayama H; Zhang P; Liu S; Makokha GN; Tsuge M; Imamura M; Hayes CN; Chayama K
    Ther Adv Med Oncol; 2020; 12():1758835920922051. PubMed ID: 32547646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib.
    Liu B; Shang X; Shi JY; Cui GZ; Li X; Wang NY
    Front Oncol; 2022; 12():807189. PubMed ID: 35251977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Yang Z; Suda G; Maehara O; Ohara M; Yoshida S; Hosoda S; Kimura M; Kubo A; Tokuchi Y; Fu Q; Yamada R; Kitagataya T; Suzuki K; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Sakamoto N
    Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer.
    Kumagai M; Nagahama M; Akamine Y; Ozeki T; Suzuki A; Sugino K; Ito K; Miura M
    Cancer Diagn Progn; 2022; 2(3):336-344. PubMed ID: 35530647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.
    Maeda T; Kanzaki H; Chiba T; Ao J; Kanayama K; Maruta S; Kusakabe Y; Saito T; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Nakagawa R; Muroyama R; Kanda T; Maruyama H; Kato N
    BMC Cancer; 2019 Nov; 19(1):1088. PubMed ID: 31718608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.
    Zhang ZL; Liu ZS; Sun Q
    World J Gastroenterol; 2006 Jul; 12(26):4241-5. PubMed ID: 16830384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
    Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study.
    Hidaka H; Uojima H; Nakazawa T; Shao X; Hara Y; Iwasaki S; Wada N; Kubota K; Tanaka Y; Shibuya A; Kanoh Y; Kokubu S; Koizumi W
    Hepatol Res; 2020 Sep; 50(9):1083-1090. PubMed ID: 32515895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
    Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
    Kudo M; Ueshima K; Chan S; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida N
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
    Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.